Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

HIK PEER ANALYSIS

Hikma Pharmaceuticals PLC — metric-by-metric comparison with peers and the industry median

HIKHikma Pharmaceuticals PLC

🇬🇧 UK · LSE · Healthcare · Drug Manufacturers - Specialty & Generic

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - Specialty & Generic

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
HIKIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
HIK-18.5%TRILC-94.3%ASRT+140.7%ANIK+42.5%BTAI-43.0%SIGA-36.6%
Year-to-Date (YTD)
HIK+2.5%TRILC-92.8%ASRT+159.1%ANIK+66.8%BTAI-31.3%SIGA-30.6%
1-Year
Split-adjusted
HIK-18.5%HLN-3.3%
Year-to-Date (YTD)
HIK+2.5%HLN-3.1%

Key Metric Comparison

P/E

Lower is better
HIK11.40TRILC—ASRT—ANIK—BTAI—SIGA13.26Median 21.35

ROE

Higher is better
HIK16.4%TRILC-6.0%ASRT-38.8%ANIK-7.8%BTAI—SIGA11.0%Median 6.4%

Net Margin

Higher is better
HIK12.0%TRILC-2.2%ASRT-34.9%ANIK-9.5%BTAI-11,078.5%SIGA21.6%Median 4.0%

Revenue Growth

Higher is better
HIK7.4%TRILC32.0%ASRT-14.2%ANIK23.2%BTAI-63.3%SIGA-22.1%Median 7.5%

P/E

Lower is better
HIK11.40HLN30.79Median 21.35

ROE

Higher is better
HIK16.4%HLN6.3%Median 6.4%

Net Margin

Higher is better
HIK12.0%HLN12.6%Median 4.0%

Revenue Growth

Higher is better
HIK7.4%HLN-26.7%Median 7.5%

All Metrics

Valuation
MetricHIKTRILCASRTANIKBTAISIGAInd. Median
P/E11.40●————13.2621.35
P/B1.770.612.001.62-0.13●1.771.77
EV/EBITDA8.723.51●———4.5012.18
P/S1.370.23●1.481.8719.752.872.08
Financial Health
MetricHIKTRILCASRTANIKBTAISIGAInd. Median
Current Ratio1.820.991.824.46●0.623.252.22
Debt/Equity61.8%207.6%53.3%19.2%-95.0%●0.4%46.3%
NetDebt/EBITDA1.872.715.393.30-1.44-5.27●1.24
Profitability
MetricHIKTRILCASRTANIKBTAISIGAInd. Median
Net Margin12.0%-2.2%-34.9%-9.5%-11,078.5%21.6%●4.0%
ROE16.4%●-6.0%-38.8%-7.8%—11.0%6.4%
ROA7.5%-1.8%-14.3%-6.0%-207.6%8.7%●3.4%
EBITDA Margin20.0%28.5%-5.7%-4.0%-8,509.3%29.3%●18.2%
Growth + Dividend
MetricHIKTRILCASRTANIKBTAISIGAInd. Median
Rev. Growth7.4%32.0%●-14.2%23.2%-63.3%-22.1%7.5%
NI Growth12.2%●————-58.2%5.0%
Div. Yield5.4%0.0%———16.1%●2.0%
Payout45.2%0.0%———213.6%0.8%
Valuation
MetricHIKHLNInd. Median
P/E11.40●30.7921.35
P/B1.77●1.941.77
EV/EBITDA8.72●18.9012.18
P/S1.37●3.872.08
Financial Health
MetricHIKHLNInd. Median
Current Ratio1.82●0.922.22
Debt/Equity61.8%52.3%●46.3%
NetDebt/EBITDA1.87●3.501.24
Profitability
MetricHIKHLNInd. Median
Net Margin12.0%12.6%●4.0%
ROE16.4%●6.3%6.4%
ROA7.5%●3.2%3.4%
EBITDA Margin20.0%25.2%●18.2%
Growth + Dividend
MetricHIKHLNInd. Median
Rev. Growth7.4%●-26.7%7.5%
NI Growth12.2%●-14.2%5.0%
Div. Yield5.4%●2.0%2.0%
Payout45.2%40.0%0.8%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on HIK

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.